Literature DB >> 34966532

Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies.

Anjan Dhar1, Frances Maw2, Helen Jane Dallal1, Stephen Attwood3.   

Abstract

The two main drugs used in the treatment of gastro-oesophageal reflux disease are proton pump inhibitors and histamine-2 receptor antagonists and both these agents have been implicated in a number of adverse effects, leading to considerable controversies related to their long-term use. This paper is aimed at a critical review of the published literature and the clinical significance of these reported side effects, most of which are associations rather than causal. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acid-related diseases; adverse drug reactions; gastroesophageal reflux disease

Year:  2020        PMID： 34966532      PMCID： PMC8666855          DOI： 10.1136/flgastro-2019-101386

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


  25 in total

Review 1.  Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies.

Authors:  Wisit Cheungpasitporn; Charat Thongprayoon; Wonngarm Kittanamongkolchai; Narat Srivali; Peter J Edmonds; Patompong Ungprasert; Oisin A O'Corragain; Sira Korpaisarn; Stephen B Erickson
Journal:  Ren Fail       Date:  2015-06-25       Impact factor: 2.606

2.  Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.

Authors:  S E Attwood; C Ell; J P Galmiche; R Fiocca; J G Hatlebakk; B Hasselgren; G Långström; M Jahreskog; S Eklund; T Lind; L Lundell
Journal:  Aliment Pharmacol Ther       Date:  2015-04-10       Impact factor: 8.171

Review 3.  Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis.

Authors:  Leonardo H Eusebi; Raguprakash Ratnakumaran; Yuhong Yuan; Masoud Solaymani-Dodaran; Franco Bazzoli; Alexander C Ford
Journal:  Gut       Date:  2017-02-23       Impact factor: 23.059

4.  Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Authors:  Paul Moayyedi; John W Eikelboom; Jackie Bosch; Stuart J Connolly; Leanne Dyal; Olga Shestakovska; Darryl Leong; Sonia S Anand; Stefan Störk; Kelley R H Branch; Deepak L Bhatt; Peter B Verhamme; Martin O'Donnell; Aldo P Maggioni; Eva M Lonn; Leopoldo S Piegas; Georg Ertl; Matyas Keltai; Nancy Cook Bruns; Eva Muehlhofer; Gilles R Dagenais; Jae-Hyung Kim; Masatsugu Hori; P Gabriel Steg; Robert G Hart; Rafael Diaz; Marco Alings; Petr Widimsky; Alvaro Avezum; Jeffrey Probstfield; Jun Zhu; Yan Liang; Patricio Lopez-Jaramillo; Ajay K Kakkar; Alexander N Parkhomenko; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Dragos Vinereanu; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; Kaj P Metsarinne; Keith A A Fox; Salim Yusuf
Journal:  Gastroenterology       Date:  2019-05-29       Impact factor: 22.682

Review 5.  Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.

Authors:  Johnson W McRorie; James A Kirby; Philip B Miner
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

6.  Proton-pump inhibitors and risk of fractures: an update meta-analysis.

Authors:  B Zhou; Y Huang; H Li; W Sun; J Liu
Journal:  Osteoporos Int       Date:  2016-01       Impact factor: 4.507

Review 7.  Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.

Authors:  Wai-Kit Lo; Walter W Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2012-12-24       Impact factor: 11.382

8.  Summary of Recommendation Statements.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

9.  PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis.

Authors:  Alexandra Demcsák; Tamás Lantos; Emese Réka Bálint; Petra Hartmann; Áron Vincze; Judit Bajor; László Czopf; Hussain Alizadeh; Zoltán Gyöngyi; Katalin Márta; Alexandra Mikó; Zsolt Szakács; Dániel Pécsi; Péter Hegyi; Imre László Szabó
Journal:  Front Physiol       Date:  2018-11-19       Impact factor: 4.566

10.  Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Authors:  Janusz A Z Jankowski; John de Caestecker; Sharon B Love; Gavin Reilly; Peter Watson; Scott Sanders; Yeng Ang; Danielle Morris; Pradeep Bhandari; Claire Brooks; Stephen Attwood; Rebecca Harrison; Hugh Barr; Paul Moayyedi
Journal:  Lancet       Date:  2018-07-26       Impact factor: 202.731
View more
  1 in total

1.  British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Authors:  Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill
Journal:  Gut       Date:  2022-05-23       Impact factor: 31.793
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.